Enzo Biochem, Inc.  

(Public, NYSE:ENZ)   Watch this stock  
Find more results for ENZ
2.20
+0.03 (1.38%)
Jun 17 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 2.16 - 2.25
52 week 1.33 - 3.16
Open 2.18
Vol / Avg. 69,630.00/91,853.00
Mkt cap 86.63M
P/E     -
Div/yield     -
EPS -1.02
Shares 39.38M
Beta 1.69
Inst. own 38%
Jun 11, 2013
Q3 2013 Enzo Biochem Earnings Conference Call - Webcast
Jun 10, 2013
Q3 2013 Enzo Biochem Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Jan '13) 2012
Net profit margin -25.55% -38.09%
Operating margin -26.99% -39.27%
EBITD margin - -11.12%
Return on average assets -35.22% -43.97%
Return on average equity -52.93% -56.99%
Employees 467 -
Carbon Disclosure Rating - -

Address

527 Madison Avenue
NEW YORK, NY 10022
United States - Map
+1-212-5830100 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Enzo Biochem, Inc. (Enzo), is an integrated life sciences and biotechnology company. Enzo has three segments: Enzo Clinical Labs, Enzo Life Sciences, and Enzo Therapeutics. Enzo focused on harnessing biological processes to develop research tools, diagnostics and therapeutics and serves as a provider of test services, including esoteric tests, to the medical community. The Company has developed a portfolio of technologies with a variety of research, diagnostic and therapeutic applications. Enzo Clinical Labs segment is a regional clinical laboratory serving the New York, New Jersey and Eastern Pennsylvania medical communities. The Company's Enzo Life Sciences manufactures, develops and markets products and tools to life sciences, drug development and clinical research customers world-wide. The Company's Enzo Therapeutics segment is a biopharmaceutical venture that develops multiple approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases.

Officers and directors

Barry W. Weiner President, Chief Financial Officer, Principal Accounting Officer, Treasurer, Director
Age: 62
Bio & Compensation  - Reuters
Elazar Rabbani Ph.D. Chairman of the Board, Chief Executive Officer, Secretary
Age: 69
Bio & Compensation  - Reuters
Andrew R Crescenzo CPA Senior Vice President - Finance
Age: 56
Bio & Compensation  - Reuters
Herbert B. Bass Vice President - Finance
Age: 64
Bio & Compensation  - Reuters
Paul C. O'Brien Vice President - Global Human Resources
Age: 50
Bio & Compensation  - Reuters
David C. Goldberg Vice President - Corporate Development; Interim General Manager of Enzo Clinical Labs
Age: 55
Bio & Compensation  - Reuters
Andrew P. Whiteley Chief Operating Officer of Enzo Life Sciences, Inc.,
Age: 54
Bio & Compensation  - Reuters
Bernard L. Kasten Jr., M.D. Lead Independent Director
Age: 66
Bio & Compensation  - Reuters
Dov Perlysky Director
Age: 50
Bio & Compensation  - Reuters
Gregory M. Bortz Independent Director
Age: 43
Bio & Compensation  - Reuters